Financial Analysis: Biosig Technologies (STEX) & Its Competitors

Biosig Technologies (NASDAQ:STEX) is one of 28 public companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it contrast to its competitors? We will compare Biosig Technologies to similar companies based on the strength of its profitability, dividends, earnings, institutional ownership, risk, analyst recommendations and valuation.

Valuation & Earnings

This table compares Biosig Technologies and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Biosig Technologies	$40,000.00	-$10.33 million	-1.84
Biosig Technologies Competitors	$59.54 million	-$32.15 million	4.02

Biosig Technologies’ competitors have higher revenue, but lower earnings than Biosig Technologies. Biosig Technologies is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Biosig Technologies has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, Biosig Technologies’ competitors have a beta of 1.76, meaning that their average share price is 76% more volatile than the S&P 500.

Insider & Institutional Ownership

7.2% of Biosig Technologies shares are owned by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by insiders. Comparatively, 18.1% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Biosig Technologies and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1	0	0	0	1.00
Biosig Technologies Competitors	76	75	156	6	2.29

As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 49.76%. Given Biosig Technologies’ competitors stronger consensus rating and higher probable upside, analysts clearly believe Biosig Technologies has less favorable growth aspects than its competitors.

Profitability

This table compares Biosig Technologies and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	N/A	-64.96%
Biosig Technologies Competitors	-672.41%	-133.75%	-59.01%

Summary

Biosig Technologies competitors beat Biosig Technologies on 9 of the 13 factors compared.

Biosig Technologies Company Profile

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company’s proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.